What are we doing in the field of cardiovascular disease?
Bristol Myers Squibb is committed to continuing its strong leadership and legacy in the development of transformational therapeutics or treating patients with cardiovascular disease. Our focus is both chronic and acute heart failure, with particular interest in patients with heart failure with preserved ejection fraction.
Cardiovascular diseases include all diseases affecting the cardiovascular system and the blood and lymphatic vessels, including heart attacks, strokes, and venous thromboembolism.
Every year, around 19,000 people in Belgium suffer a stroke1, while another 15,000 suffer a heart attack2. Cardiovascular disease is one of the leading causes of mortality and morbidity in industrialised countries.
Early detection of these diseases, treatment of the risk factors, and prevention are all critical in reducing the impact of cardiovascular disease. Therefore, current research at Bristol Myers Squibb is focused on developing therapies to prevent stroke and treat venous thromboembolism. Stroke prevention focuses on atrial fibrillation, one of the significant risk factors for stroke.
Available information for patients
We support patients through prevention campaigns, disease awareness campaigns, sponsorship, congresses, and events, and by working with health professionals, hospitals and renowned specialists from various patient organisations.
Bristol Myers Squibb supports FibriCoach, an online patient education programme that explains the various aspects of atrial fibrillation (AF) to newly diagnosed patients. It is a platform where patients can view information about AF and testimonials from other patients.